The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Gene therapy returns to centre stage
Abstract
Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation (allo-HSCT) can provide a one-time and life-long cure for patients with serious genetic hematological diseases such as primary immunodeficiencies20 and hemoglobinopathies21,22, if a suitable immunologically matched donor can be found23.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [23]
In the citing paper
“Although insertional mutagenesis risk has been reduced by improved vector design19, the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD20–23 has generated renewed concerns.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [19]
In the citing paper
“Gene therapy with autologous hematopoietic stem cells has been investigated as an alternative to allogeneic hematopoietic stem-cell transplantation.11–13”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
Therapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336
Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Self-citationLentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Self-citationGene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805817 · Cited by 1,007
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 911
Hematopoiesis: a human perspective
Doulatov, S., Notta, F., Laurenti, E., & Dick, J. E. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.01.006 · Cited by 895
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Repair of Strand Breaks by Homologous Recombination
Jasin, M., & Rothstein, R. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012740 · Cited by 887
Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
A prudent path forward for genomic engineering and germline gene modification
Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R. A., Church, G., Corn, J. E., Daley, G. Q., Doudna, J. A., Fenner, M., et al. (2015) · Science · doi:10.1126/science.aab1028 · Cited by 733
Stein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2088 · Cited by 716
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 701
Self-citationAn Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency
Hacein-Bey-Abina, S., Hauer, J., Lim, A., Picard, C., Wang, G. P., Berry, C. C., Martinache, C., Rieux-Laucat, F., Latour, S., Belohradsky, B. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000164 · Cited by 639
Progress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., Bondanza, A., Bordignon, C., Peccatori, J., Ciceri, F., et al. (2013) · Blood · doi:10.1182/blood-2012-05-431718 · Cited by 625
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571
Self-citationGene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity
Braun, C. J., Boztug, K., Paruzynski, A., Witzel, M., Schwarzer, A., Rothe, M., Modlich, U., Beier, R., Göhring, G., Steinemann, D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007280 · Cited by 562
Targeted genome editing in human repopulating haematopoietic stem cells
Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M. C., et al. (2014) · Nature · doi:10.1038/nature13420 · Cited by 555
Self-citationSimonelli, F., Maguire, A. M., Testa, F., Pierce, E. A., Mingozzi, F., Bennicelli, J. L., Rossi, S., Marshall, K., Banfi, S., Surace, E. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.277 · Cited by 553
In vivo genome editing restores haemostasis in a mouse model of haemophilia
Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S. Y., Bhagwat, A. S., Malani, N., Anguela, X. M., Sharma, R., Ivanciu, L., et al. (2011) · Nature · doi:10.1038/nature10177 · Cited by 548
Stem-Cell Gene Therapy for the Wiskott–Aldrich Syndrome
Boztug, K., Schmidt, M., Schwarzer, A., Banerjee, P. P., Díez, I. A., Dewey, R. A., Böhm, M., Nowrouzi, A., Ball, C. R., Glimm, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003548 · Cited by 532
Torikai, H., Reik, A., Liu, P.-Q., Zhou, Y., Zhang, L., Maiti, S., Huls, H., Miller, J. C., Kebriaei, P., Rabinovitch, B., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405365 · Cited by 528
Self-citationAn unbiased genome-wide analysis of zinc-finger nuclease specificity
Gabriel, R., Lombardo, A., Arens, A., Miller, J. C., Genovese, P., Kaeppel, C., Nowrouzi, A., Bartholomae, C. C., Wang, J., Friedman, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1948 · Cited by 526
Self-citationRecurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
Nault, J.-C., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., Verret, B., Blanc, J.-F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3389 · Cited by 489
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Selection and evaluation of clinically relevant AAV variants in a xenograft liver model
Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., Nygaard, S., Grompe, M., Alexander, I. E., & Kay, M. A. (2014) · Nature · doi:10.1038/nature12875 · Cited by 450
Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61939-x · Cited by 450
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2700 · Cited by 448
Self-citationPrimary immunodeficiencies: 2009 update
Notarangelo, L. D., Fischer, A., Geha, R. S., Casanova, J.-L., Chapel, H., Conley, M. E., Cunningham-Rundles, C., Etzioni, A., Hammartröm, L., Nonoyama, S., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.013 · Cited by 447
Gennery, A. R., Slatter, M. A., Grandin, L., Taupin, P., Cant, A. J., Veys, P., Amrolia, P. J., Gaspar, H. B., Davies, E. G., Friedrich, W., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.06.015 · Cited by 427
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency
Hacein-Bey-Abina, S., Pai, S.-Y., Gaspar, H. B., Armant, M., Berry, C. C., Blanche, S., Bleesing, J., Blondeau, J., de Boer, H., Buckland, K. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404588 · Cited by 412
Adoptive cellular therapy: A race to the finish line
June, C. H., Riddell, S. R., & Schumacher, T. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3643 · Cited by 403
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79213 · Cited by 403
Modlich, U., Navarro, S., Zychlinski, D., Maetzig, T., Knoess, S., Brugman, M. H., Schambach, A., Charrier, S., Galy, A., Thrasher, A. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.179 · Cited by 387
Improvement and Decline in Vision with Gene Therapy in Childhood Blindness
Jacobson, S. G., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Schwartz, S. B., Heon, E., & Hauswirth, W. W. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412965 · Cited by 372
Ex vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
Self-citationOutcomes Following Gene Therapy in Patients With Severe Wiskott-Aldrich Syndrome
Hacein-Bey Abina, S., Gaspar, H. B., Blondeau, J., Caccavelli, L., Charrier, S., Buckland, K., Picard, C., Six, E., Himoudi, N., Gilmour, K., et al. (2015) · JAMA · doi:10.1001/jama.2015.3253 · Cited by 357
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., Imoukhuede, E. B., Payne, R., Fehling, S. K., Strecker, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1411627 · Cited by 348
Berntorp, E., & Shapiro, A. D. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61139-2 · Cited by 335
Site-specific integration and tailoring of cassette design for sustainable gene transfer
Lombardo, A., Cesana, D., Genovese, P., Di Stefano, B., Provasi, E., Colombo, D. F., Neri, M., Magnani, Z., Cantore, A., Lo Riso, P., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1674 · Cited by 331
Self-citationTesta, F., Maguire, A. M., Rossi, S., Pierce, E. A., Melillo, P., Marshall, K., Banfi, S., Surace, E. M., Sun, J., Acerra, C., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.048 · Cited by 330
Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters
Amendola, M., Venneri, M. A., Biffi, A., Vigna, E., & Naldini, L. (2005) · Nature Biotechnology · doi:10.1038/nbt1049 · Cited by 324
Self-citationCorrection of the sickle cell disease mutation in human hematopoietic stem/progenitor cells
Hoban, M. D., Cost, G. J., Mendel, M. C., Romero, Z., Kaufman, M. L., Joglekar, A. V., Ho, M., Lumaquin, D., Gray, D., Lill, G. R., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615948 · Cited by 320
Long-term follow-up after gene therapy for canavan disease
Leone, P., Shera, D., McPhee, S. W. J., Francis, J. S., Kolodny, E. H., Bilaniuk, L. T., Wang, D.-J., Assadi, M., Goldfarb, O., Goldman, H. W., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003454 · Cited by 307
Gaspar, H. B., Cooray, S., Gilmour, K. C., Parsley, K. L., Zhang, F., Adams, S., Bjorkegren, E., Bayford, J., Brown, L., Davies, E. G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002716 · Cited by 285
X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects
Kemp, S., Berger, J., & Aubourg, P. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.03.012 · Cited by 283
Biffi, A., De Palma, M., Quattrini, A., Del Carro, U., Amadio, S., Visigalli, I., Sessa, M., Fasano, S., Brambilla, R., Marchesini, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419205 · Cited by 280
Self-citationCell culture assays reveal the importance of retroviral vector design for insertional genotoxicity
Modlich, U., Bohne, J., Schmidt, M., von Kalle, C., Knöss, S., Schambach, A., & Baum, C. (2006) · Blood · doi:10.1182/blood-2005-08-024976 · Cited by 278
Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors
Zychlinski, D., Schambach, A., Modlich, U., Maetzig, T., Meyer, J., Grassman, E., Mishra, A., & Baum, C. (2008) · Molecular Therapy · doi:10.1038/mt.2008.5 · Cited by 271
Adoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264
Tardieu, M., Zérah, M., Husson, B., de Bournonville, S., Deiva, K., Adamsbaum, C., Vincent, F., Hocquemiller, M., Broissand, C., Furlan, V., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.238 · Cited by 261
Biffi, A., De Palma, M., Quattrini, A., Del Carro, U., Amadio, S., Visigalli, I., Sessa, M., Fasano, S., Brambilla, R., Marchesini, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19205 · Cited by 261
Self-citationPromoterless gene targeting without nucleases ameliorates haemophilia B in mice
Barzel, A., Paulk, N. K., Shi, Y., Huang, Y., Chu, K., Zhang, F., Valdmanis, P. N., Spector, L. P., Porteus, M. H., Gaensler, K. M., et al. (2015) · Nature · doi:10.1038/nature13864 · Cited by 257
Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission
Balazs, A. B., Ouyang, Y., Hong, C. M., Chen, J., Nguyen, S. M., Rao, D. S., An, D. S., & Baltimore, D. (2014) · Nature Medicine · doi:10.1038/nm.3471 · Cited by 237
Assessing the potential for AAV vector genotoxicity in a murine model
Li, H., Malani, N., Hamilton, S. R., Schlachterman, A., Bussadori, G., Edmonson, S. E., Shah, R., Arruda, V. R., Mingozzi, F., Fraser Wright, J., et al. (2011) · Blood · doi:10.1182/blood-2010-08-302729 · Cited by 236
Candotti, F., Shaw, K. L., Muul, L., Carbonaro, D., Sokolic, R., Choi, C., Schurman, S. H., Garabedian, E., Kesserwan, C., Jagadeesh, G. J., et al. (2012) · Blood · doi:10.1182/blood-2012-02-400937 · Cited by 234
Gaspar, H. B., Cooray, S., Gilmour, K. C., Parsley, K. L., Adams, S., Howe, S. J., Al Ghonaium, A., Bayford, J., Brown, L., Davies, E. G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002715 · Cited by 232
Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice
Biffi, A., Capotondo, A., Fasano, S., Carro, U. D., Marchesini, S., Azuma, H., Malaguti, M. C., Amadio, S., Brambilla, R., Grompe, M., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28873 · Cited by 221
Self-citationNew viruses for cancer therapy: meeting clinical needs
Miest, T. S., & Cattaneo, R. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3140 · Cited by 220
Biffi, A., Bartolomae, C. C., Cesana, D., Cartier, N., Aubourg, P., Ranzani, M., Cesani, M., Benedicenti, F., Plati, T., Rubagotti, E., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306761 · Cited by 216
Self-citationMetachromatic Leukodystrophy – An Update
Gieselmann, V., & Krägeloh-Mann, I. (2010) · Neuropediatrics · doi:10.1055/s-0030-1253412 · Cited by 215
Capotondo, A., Milazzo, R., Politi, L. S., Quattrini, A., Palini, A., Plati, T., Merella, S., Nonis, A., di Serio, C., Montini, E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205858109 · Cited by 200
Self-citationAdeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
Kang, E. M., Choi, U., Theobald, N., Linton, G., Long Priel, D. A., Kuhns, D., & Malech, H. L. (2010) · Blood · doi:10.1182/blood-2009-05-222760 · Cited by 190
Li, L., Krymskaya, L., Wang, J., Henley, J., Rao, A., Cao, L.-F., Tran, C.-A., Torres-Coronado, M., Gardner, A., Gonzalez, N., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.65 · Cited by 181
Girard-Gagnepain, A., Amirache, F., Costa, C., Lévy, C., Frecha, C., Fusil, F., Nègre, D., Lavillette, D., Cosset, F.-L., & Verhoeyen, E. (2014) · Blood · doi:10.1182/blood-2014-02-558163 · Cited by 178
Biasco, L., Scala, S., Basso Ricci, L., Dionisio, F., Baricordi, C., Calabria, A., Giannelli, S., Cieri, N., Barzaghi, F., Pajno, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010314 · Cited by 175
20 years of gene therapy for SCID
Fischer, A., Hacein-Bey-Abina, S., & Cavazzana-Calvo, M. (2010) · Nature Immunology · doi:10.1038/ni0610-457 · Cited by 165
Martino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
Liver-directed lentiviral gene therapy in a dog model of hemophilia B
Cantore, A., Ranzani, M., Bartholomae, C. C., Volpin, M., Valle, P. D., Sanvito, F., Sergi, L. S., Gallina, P., Benedicenti, F., Bellinger, D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1405 · Cited by 158
Self-citationCRISPR germline engineering—the community speaks
Bosley, K., Botchan, M. R., Bredenoord, A. L., Carroll, D., Charo, R. A., Charpentier, E., Cohen, R., Corn, J. E., Doudna, J. A., Feng, G., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3227 · Cited by 141
Self-citationFanconi Anemia Gene Editing by the CRISPR/Cas9 System
Osborn, M. J., Gabriel, R., Webber, B. R., DeFeo, A. P., McElroy, A. N., Jarjour, J., Starker, C. G., Wagner, J. E., Joung, J. K., Voytas, D. F., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.111 · Cited by 130
Ogwang, C., Kimani, D., Edwards, N. J., Roberts, R., Mwacharo, J. K., Bowyer, G., Bliss, C. M., Hodgson, S. H. C., Njuguna, P., Viebig, N. K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2373 · Cited by 129
Lentiviral Hematopoietic Cell Gene Therapy for X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Bougnères, P., Schmidt, M., Von Kalle, C., Fischer, A., Cavazzana-Calvo, M., & Aubourg, P. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00010-7 · Cited by 123
Improving the safety of cell therapy with the TK-suicide gene
Greco, R., Oliveira, G., Stanghellini, M. T. L., Vago, L., Bondanza, A., Peccatori, J., Cieri, N., Marktel, S., Mastaglio, S., Bordignon, C., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00095 · Cited by 122
Zhou, S., Mody, D., DeRavin, S. S., Hauer, J., Lu, T., Ma, Z., Hacein-Bey Abina, S., Gray, J. T., Greene, M. R., Cavazzana-Calvo, M., et al. (2010) · Blood · doi:10.1182/blood-2009-10-250209 · Cited by 119
Beane, J. D., Lee, G., Zheng, Z., Mendel, M. C., Abate‐Daga, D., Bharathan, M., Black, M. A., Gandhi, N. H., Yu, Z., Chandran, S. S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.71 · Cited by 116
Retroviral Gene Therapy for X-linked Chronic Granulomatous Disease: Results From Phase I/II Trial
Kang, H. J., Bartholomae, C. C., Paruzynski, A., Arens, A., Kim, S., Yu, S. S., Hong, Y., Joo, C.-W., Yoon, N., Rhim, J. W., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.166 · Cited by 109
$1-million price tag set for Glybera gene therapy
Morrison, C. (2015) · Nature Biotechnology · doi:10.1038/nbt0315-217 · Cited by 107
Current status of haemophilia gene therapy
High, K. A., Nathwani, A. C., Spencer, H. T., & Lillicrap, D. (2014) · Haemophilia · doi:10.1111/hae.12411 · Cited by 90
The special case of gene therapy pricing
Brennan, T. A., & Wilson, J. M. (2014) · Nature Biotechnology · doi:10.1038/nbt.3003 · Cited by 77
Targeted gene therapy and cell reprogramming in Fanconi anemia
Río, P., Baños, R., Lombardo, A., Bustamante, O. Q., Alvarez, L. A., Garate, Z., Genovese, P., Almarza, E., Valeri, A., Díez, B., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201303374 · Cited by 73
Self-citationUpdate on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency
Ferrua, F., Brigida, I., & Aiuti, A. (2010) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32833fea85 · Cited by 68
Krägeloh‐Mann, I., Groeschel, S., Kehrer, C., Opherk, K., Nägele, T., Handgretinger, R., & Müller, I. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.155 · Cited by 67
Regulatory evaluation of Glybera in Europe — two committees, one mission
Melchiorri, D., Pani, L., Gasparini, P., Cossu, G., Ancāns, J., Borg, J.-J., Drai, C., Fiedor, P. S., Flory, E., Hudson, I., et al. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3835-c1 · Cited by 60
Deichmann, A., Brugman, M. H., Bartholomae, C. C., Schwarzwaelder, K., Verstegen, M. M. A., Howe, S. J., Arens, A., Ott, M., Hoelzer, D. F., Seger, R. A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.178 · Cited by 57
Concise Review: Managing Genotoxicity in the Therapeutic Modification of Stem Cells
Baum, C., Modlich, U., Göhring, G., & Schlegelberger, B. (2011) · Stem Cells · doi:10.1002/stem.716 · Cited by 44
Long-Term Effects of Retinal Gene Therapy in Childhood Blindness
Wright, A. F. (2015) · New England Journal of Medicine · doi:10.1056/nejme1503419 · Cited by 29
The road to purified hematopoietic stem cell transplants is paved with antibodies
Logan, A. C., Weissman, I. L., & Shizuru, J. A. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.002 · Cited by 25
Memory T Cells Officially Join the Stem Cell Club
Gattinoni, L. (2014) · Immunity · doi:10.1016/j.immuni.2014.07.003 · Cited by 24
Zhou, S., Ma, Z., Lu, T., Janke, L. J., Gray, J. T., & Sorrentino, B. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062333 · Cited by 23
Gene therapy outpaces haplo for SCID-X1
Kohn, D. B. (2015) · Blood · doi:10.1182/blood-2015-04-641720 · Cited by 8
Research works printed but not linked: 1
- Baxter. Baxalta reports continued progress on phase 1/2 clinical trial of BAX335, investigational gene therapy treatment for hemophilia B. Baxter http://www.baxter.com/news-media/newsroom/press-releases/2015/06_24_15_bax335.page (2015).
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies
Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N. J., & Xu, J. (2018) · Bone Research · doi:10.1038/s41413-018-0016-9 · Cited by 1,767
“Gene therapy means that treating RA by inserting a gene into a patient’s cells instead of using drugs.(147) Targeting gene therapy in RA is a treatment strategy that is still in very early stages of development but could lead to new possibilities because of treating a disease at its root.”
BackgroundThe next generation of CRISPR–Cas technologies and applications
Pickar-Oliver, A., & Gersbach, C. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0131-5 · Cited by 1,459
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“Long-term cell replacement afforded by genetically engineered hematopoietic stem cells (HSCs) may durably alleviate a range of conditions, obviating, for example, the need for lifelong enzyme administration or transfusion therapy (3, 4).”
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
Metadata
- Authors
- Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Naldini, Luigi
- ORCID
- Naldini, Luigi
- Venue
- Nature
- Published
- 2015-10
- Volume
- 526
- Issue
- 7573
- Pages
- 351-360
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1902159756
- Semantic Scholar
- 334eb76dbe52abdfcdb4be9aa772d017378a95d3
- Cited by
- 1,184
- References
- 124
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 59 · 2023: 75 · 2022: 76 · 2021: 99 · 2020: 141 · 2019: 132 · 2018: 182 · 2017: 158 · 2016: 109 · 2015: 7
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- gene therapy, clinical trials, gene therapy vectors, genome editing, inherited mutations, stem cell therapy, tissue regeneration, cancer immunotherapy, gene therapy safety
- MeSH terms
- Clinical Trials as Topic, Hematopoietic Stem Cells, Humans, Immunotherapy, Liver, Neoplasms, Organ Specificity, T-Lymphocytes, Genetic Therapy, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.